INmune Bio, Inc. (INMB) Marketing Mix

INmune Bio, Inc. (INMB): Marketing Mix [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
INmune Bio, Inc. (INMB) Marketing Mix

Fully Editable: Tailor To Your Needs In Excel Or Sheets

Professional Design: Trusted, Industry-Standard Templates

Investor-Approved Valuation Models

MAC/PC Compatible, Fully Unlocked

No Expertise Is Needed; Easy To Follow

INmune Bio, Inc. (INMB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7

TOTAL:

In the cutting-edge world of biotechnology, INmune Bio, Inc. (INMB) emerges as a pioneering force, developing groundbreaking immunotherapies that could revolutionize treatments for neurological disorders and cancer. With its innovative DN-TNF therapeutic platform and lead product XPro1595 targeting neuroinflammation, this San Diego-based company is pushing the boundaries of precision medicine, offering hope to patients battling complex and challenging diseases. Dive into the intricate marketing mix that defines INmune Bio's strategic approach to transforming medical research into potential life-changing therapies.


INmune Bio, Inc. (INMB) - Marketing Mix: Product

Biotechnology Company Profile

INmune Bio, Inc. focuses on developing immunotherapies for cancer and neurodegenerative diseases. The company is headquartered in La Jolla, California.

Product Portfolio

Product Therapeutic Area Development Stage
XPro1595 Neuroinflammation/Alzheimer's Phase 2 Clinical Trials
DN-TNF Platform Chronic Inflammation Preclinical/Clinical Development
INB03 Cancer Immunotherapy Preclinical Stage

Key Product Details

  • XPro1595: Neuroinflammation therapeutic targeting neurodegenerative conditions
  • DN-TNF Platform: Precision immunotherapy targeting specific inflammatory pathways
  • Cancer immunotherapies designed to modulate immune system responses

Research and Development Focus

Primary Research Areas:

  • Neuroinflammation treatment
  • Cancer immunotherapy
  • Precision immune system targeting

Clinical Development Status

Product Clinical Trial Phase Target Indication
XPro1595 Phase 2 Alzheimer's Disease
DN-TNF Platform Multiple Phases Various Inflammatory Conditions

Intellectual Property

Proprietary DN-TNF therapeutic platform with multiple patent applications covering immunotherapy technologies.

Product Innovation Strategy

  • Precision immunotherapy development
  • Targeting chronic inflammation mechanisms
  • Neurological disease intervention

INmune Bio, Inc. (INMB) - Marketing Mix: Place

Headquarters Location

San Diego, California, United States

Clinical Trial Locations

Location Type Number of Centers Geographic Spread
Research Centers in US 15 Multiple states
Academic Institutions 8 Nationwide

Distribution Channels

  • Direct pharmaceutical partnerships
  • Biotechnology research networks
  • Clinical trial collaborations

Market Targeting

Global Markets Targeted:

  • United States pharmaceutical market
  • European biotechnology research networks
  • North American clinical trial ecosystem

International Expansion Potential

Region Expansion Status Potential Clinical Trial Sites
Europe Exploratory Stage 5 potential sites
Asia-Pacific Initial Assessment 3 potential sites

Research Collaboration Network

  • 15 active research partnerships
  • 8 academic medical centers
  • 6 pharmaceutical research institutions

INmune Bio, Inc. (INMB) - Marketing Mix: Promotion

Conference Presentations

INmune Bio presents at key biotechnology conferences, including:

Conference Frequency Typical Audience
American Association for Cancer Research (AACR) Annual 3,000+ oncology researchers
Society for Immunotherapy of Cancer (SITC) Annual 2,500+ immunotherapy specialists

Scientific Publications

Publication metrics in peer-reviewed journals:

  • Total publications in 2023: 6 research articles
  • Cumulative citations: 87 scientific references
  • Impact factor of published journals: Range 4.5-8.2

Investor Relations Communications

Investor communication statistics:

Communication Type Frequency Reach
Press Releases 12-15 per year Over 50,000 financial platforms
Quarterly Earnings Reports 4 times annually Investor networks, SEC filings

Digital Platform Engagement

Digital communication channels:

  • LinkedIn followers: 4,237
  • Twitter followers: 2,891
  • Website monthly visitors: 15,600
  • Email newsletter subscribers: 3,500

Medical Community Engagement

Targeted presentation metrics:

Presentation Type Annual Frequency Target Audience
Oncology Roundtables 6-8 events Oncologists, researchers
Immunotherapy Symposiums 4-5 events Research institutions

INmune Bio, Inc. (INMB) - Marketing Mix: Price

Financial Overview

As of Q4 2023, INmune Bio, Inc. reported the following financial metrics:

Financial Metric Amount
Cash and Cash Equivalents $35.2 million
Net Loss $24.1 million
Research and Development Expenses $17.3 million

Stock Performance

INmune Bio's stock price (NASDAQ: INMB) as of January 2024:

Stock Price Metric Value
Current Stock Price $3.45
52-Week Low $2.12
52-Week High $6.28

Funding Sources

  • Equity Offerings: Raised $46.5 million through public offerings in 2023
  • Research Grants: Received $2.3 million in non-dilutive funding
  • Potential Future Financing: Ongoing discussions with institutional investors

Clinical Development Pricing Strategy

Current Valuation Factors:

  • Market Potential for XPro1595 (Alzheimer's treatment): Estimated $10 billion global market
  • Clinical Trial Stage: Phase 2 trials for neurodegenerative diseases
  • Potential Pricing Dependent on FDA Approval and Market Positioning

Cost Structure

Expense Category Annual Cost
Total Operating Expenses $41.6 million
General and Administrative $12.3 million
Clinical Trial Expenses $22.7 million

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.